What is Carfilzomib?

Category: Prescription Drugs

Most popular types: Kyprolis

false

See also: Carfilzomib-lenalidomide-dexamethasone

Carfilzomib is an injectable antineoplastic product used for the treatment of multiple myeloma. This agent helps the body stop or slow the production of unwanted cancer cells and as a result may work to inhibit tumor growth.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
2
Moderate
7
Mild
2
None
0

Commonly reported side effects and conditions associated with Carfilzomib

Side effect Patients
Fatigue 3
Peripheral neuropathy 2
Exhaustion 1
Hoarseness 1
Nausea and vomiting 1
Overwhelming fatigue 1

Show all 13 reported side effects

Dosages

Based on patients currently taking Carfilzomib

Dosage Patients
30 other weekly 1
60 mg weekly 1
900 mg weekly 1

Why patients stopped taking Carfilzomib

Multiple reasons could be selected

Reason Patients
Other 2
Side effects too severe 2
Course of treatment ended 1
Did not seem to work 1
Doctor's advice 1
See all 7 patients who've stopped taking Carfilzomib

Duration

Currently taking Carfilzomib

Duration Patients
1 - 6 months 1
6 months - 1 year 2
5 - 10 years 1

Stopped taking Carfilzomib

Duration Patients
Less than 1 month 2
1 - 6 months 1
6 months - 1 year 2
1 - 2 years 1
2 - 5 years 1
Adherence
Adherence Evaluations
Always 8
Usually 1
Sometimes 0
Never taken as prescribed 2
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 3
A little hard to take 5
Not at all hard to take 3
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 5
Not specified 6

What people switch to and from

Patients started taking Carfilzomib after stopping:

Treatment Patients
Lenalidomide (Revlimid) 3
Bortezomib (Velcade) 2
Bortezomib-lenalidomide-dexamethasone (VRd) 1
Elotuzumab (Empliciti) 1
Pomalidomide (Pomalyst) 1

Show all 6 treatments patients report switching from

Patients stopped taking Carfilzomib and switched to:

Treatment Patients
Daratumumab (Darzalex) 1
Ixazomib (Ninlaro) 1
Lenalidomide (Revlimid) 1
Pomalidomide (Pomalyst) 1
Last updated:
There are no evaluations for Carfilzomib.